Megan Hansen, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 574 Main St, S Weymouth, MA 02190 Phone: 781-331-2533 Fax: 781-340-1337 |
Ms. Marie Kathleen Carey Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 574 Main St, S Weymouth, MA 02190 Phone: 781-331-2533 |
News Archive
Anika Therapeutics, Inc., a leader in products for tissue protection, healing and repair, based on hyaluronic acid technology, announced today that they had been served with a complaint alleging patent infringement with respect to the MONOVISC product by Genzyme Corporation.
The U.S. Food and Drug Administration has cleared for marketing a new source plasma collection system developed by Fenwal, Inc., the company announced today. Called the Aurora plasmapheresis system, the new device can support two-way, wireless data communication designed to eliminate manual steps and increase operator and donor satisfaction.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.
Researchers from Fox Chase Cancer Center will present data at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1, which shows the discovery of potential biomarkers that may be used to identify patients with head and neck cancer whose tumors are unlikely to respond to treatment by the targeted therapy cetuximab-a type of monoclonal antibody.
Among the most commonly used treatments for irritable bowel syndrome - which affects as many as 20 percent of the United States population - a targeted antibiotic was shown to be the safest in a new study by Cedars-Sinai researchers, based on an analysis of 26 large-scale clinical trials.
› Verified 9 days ago